6CM
CTNM

683 Capital Management’s Contineum Therapeutics CTNM Stock Holding History

683 Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$718K Sell
55,000
-36,442
-40% -$489K 0.04% 159
2025
Q4 		$1.05M Buy
+91,442
New +$1.04M 0.05% 136

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

683 Capital Management's CTNM Position: Q1 2026 in Review

683 Capital Management reduced its Contineum Therapeutics (CTNM) stake by 40% in Q1 2026, selling an estimated $489K and leaving 55,000 shares worth $718K. The position accounts for 0.04% of the portfolio, ranked #159.

683 Capital Management first reported a position in CTNM in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.05M in Q4 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • 683 Capital Management held 55,000 shares of Contineum Therapeutics worth $718K as of Q1 2026.
  • 683 Capital Management sold 36,442 Contineum Therapeutics shares in Q1 2026, an estimated $489K.
  • Contineum Therapeutics made up 0.04% of 683 Capital Management's portfolio in Q1 2026, its #159 holding.
  • 683 Capital Management first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 683 Capital Management's Contineum Therapeutics position peaked at $1.05M in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.